BiotechTube

mRNA-1273.214

Phase 3Completed
0 views this week 0 watching
0
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

SARS-CoV-2

Conditions

SARS-CoV-2

Trial Timeline

Jun 21, 2022 → Oct 20, 2025

NCT ID
NCT05436834

About mRNA-1273.214

mRNA-1273.214 is a phase 3 stage product being developed by Moderna for SARS-CoV-2. The current trial status is completed. This product is registered under clinical trial identifier NCT05436834. Target conditions include SARS-CoV-2.

What happened to similar drugs?

4 of 20 similar drugs in SARS-CoV-2 were approved

Approved (4) Terminated (1) Active (16)
🔄mRNA-1273ModernaPhase 3
🔄mRNA-1273ModernaPhase 3
🔄mRNA-1083ModernaPhase 3
🔄mRNA-1273ModernaPhase 3
🔄mRNA-1273.211ModernaPhase 3
🔄mRNA-1273ModernaPhase 3
✅mRNA-1273 Variant-containing FormulationModernaApproved

Clinical Trials (2)

NCT IDPhaseStatus
NCT05584202Phase 2Terminated
NCT05436834Phase 3Completed

Competing Products

20 competing products in SARS-CoV-2

See all competitors
ProductCompanyStageHype Score
mRNA-1010ModernaPhase 1
0
mRNA-1273ModernaPreclinical
0
mRNA-1273ModernaPhase 1
0
mRNA-1283ModernaPhase 1
0
mRNA-1273ModernaPreclinical
0
mRNA-1083 Composition 1 Dose A Lot AModernaPhase 2
0
mRNA-1273.214ModernaPhase 2
0
SPIKEVAXModernaPreclinical
0
mRNA-1273ModernaPhase 3
0
mRNA-1273ModernaPhase 3
0
mRNA-1273ModernaPreclinical
0
mRNA-1083.1ModernaPhase 2
0
SPIKEVAX BivalentModernaPreclinical
0
mRNA-1083ModernaPhase 3
0
mRNA-1273ModernaPhase 2
0
mRNA-1073ModernaPhase 2
0
mRNA-1273ModernaPhase 3
0
mRNA-1273ModernaPreclinical
0
mRNA-1273.211ModernaPhase 3
0
SPIKEVAX (mRNA-1273)ModernaPreclinical
0